On the other hand, a meta-analysis published in 2024 by Pozzilli et al. [2] states that the use of sphingosine-1-phosphate receptor (S1PR) modulators (including fingolimod) as DMTs increases the seizure risk significantly more than a placebo or other treatment options for MS patients. Here, S1PR1 is linked to myeloid sarcoma.